AI Article Synopsis
- - There is a critical demand for vaccines and treatments to combat COVID-19, which relies on effective testing methods to assess immune responses and identify promising antiviral candidates.
- - Researchers have created a new virus strain called rVSV-SARS-CoV-2 S that mimics the entry characteristics of SARS-CoV-2, allowing for better assessment of immune responses against it.
- - The study demonstrates that this recombinant virus can be used in high-throughput assays to evaluate neutralizing antibodies from recovered COVID-19 patients, paving the way for targeted therapies and deeper understanding of how the virus enters cells.
Article Abstract
There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332447 | PMC |
| http://dx.doi.org/10.1016/j.chom.2020.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!